Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngeneā€™s platform for fully integrated therapeutic discovery and development across large and small molecules.Ā 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support theirĀ Ā R&DĀ Ā goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

Press Releases

Explore our archive of official statements and announcements, covering financial results, important milestones, and various CSR initiatives.
Syngene reports first quarter results FY25
24th Jul, 2024
Syngene announces second year of STEM scholarship and mentorship program for women in collaboration with RICH
18th Jun, 2024
Syngene launches platform for rapid, enhanced protein production
4th Jun, 2024
Syngene reports full year and fourth quarter results
24th Apr, 2024
Syngene biologics manufacturing facility to be operational for US and European customers from mid-year
14th Mar, 2024
Syngene reports third quarter results
25th Jan, 2024
Syngene named one of Indiaā€™s Best Managed Companies by Deloitte
15th Jan, 2024
Syngene International announces the winners of the 2nd edition of the Annual Science Quiz held in Bangalore and Dakshin Kannada
11th Dec, 2023
Syngene concludes the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd
1st Dec, 2023
Syngene reports strong second quarter results
17th Oct, 2023

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details